Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

27/01/2026 Eastern Time in USA The Dow Jones Industrial Average dropped by 0.83%, closing at 49003.41 points; the Nasdaq Composite rose by 0.91%, closing at 23817.1 points; the S&P 500 Index rose by 0.41%, closing at 6978.6 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

Murano Global Investments PLC: Overnight gain 56.3%, SPAC stock surges on potential acquisition rumors and positive market sentiment

HCM III Acquisition Corp., a special purpose acquisition company (SPAC), was incorporated in the Cayman Islands on April 15, 2025. The company's primary objective is to pursue a business combination with one or more target enterprises. Potential transaction structures may include mergers, amalgamations, share exchanges, asset acquisitions, share purchases, or reorganizations. As a blank check company, HCM III Acquisition Corp. aims to provide an alternative path to public markets for prospective target businesses through these transaction mechanisms. The SPAC's strategy aligns with the growing trend of utilizing special purpose vehicles to facilitate more efficient and streamlined public listings. The company's management team is expected to leverage their industry expertise and network to identify attractive acquisition opportunities across various sectors. While specific target industries have not been disclosed, the SPAC's focus will likely be guided by market conditions and the team's assessment of high-growth potential businesses. Investors should note that, as with all SPACs, the success of HCM III Acquisition Corp. hinges on its ability to successfully identify and execute a business combination within the specified timeframe, typically 18-24 months from the initial public offering date.

The recent surge in Murano Global Investments PLC (MRNO) stock can be attributed to several factors. Firstly, as a Special Purpose Acquisition Company (SPAC), MRNO's share price is influenced by market expectations of potential merger and acquisition deals. The overnight jump of 56.3% suggests rumors or news of an impending acquisition, sparking investor enthusiasm. Secondly, the year-to-date gain of 135.3% reflects investor confidence in the company's long-term prospects. This stems from the market's recognition of SPAC investment value and faith in MRNO's management team. Lastly, positive overall market sentiment has contributed to MRNO's upward trajectory, particularly if related sectors or the SPAC segment as a whole are performing strongly. These factors collectively underscore the market's optimistic outlook on Murano Global Investments PLC (MRNO).

Richtech Robotics Inc. Class B: Overnight gain 44.6%, Strong Q4 performance and AI collaboration with Microsoft boost investor confidence in robotics prospects.

Richtech Robotics Inc. Class B, a robotics and artificial intelligence technology company founded in 2016, has positioned itself at the forefront of advanced AI systems development. The firm specializes in delivering intelligent robotic solutions across diverse sectors, including food service, retail, and industrial manufacturing. The company's product portfolio is characterized by user-friendly designs, robust reliability, and customizable features, all aimed at enhancing enterprise efficiency and productivity. Leveraging proprietary AI models trained on internal datasets, Richtech enables its robots to operate effectively in real-world environments. Strategically, Richtech Robotics Inc. Class B is pursuing a vision to establish itself as a leading robotics operator. The company aims to construct an integrated AI ecosystem, managing an extensive network of intelligent robots to support a wide array of commercial activities. This approach underscores Richtech's commitment to innovation and its ambition to play a pivotal role in the ongoing automation revolution across multiple industries. As the demand for AI-driven solutions continues to grow, Richtech Robotics Inc. Class B appears well-positioned to capitalize on emerging opportunities in the rapidly evolving robotics and AI market.

Richtech Robotics Inc. Class B (RR) experienced a significant stock price surge due to multiple factors. The company's Q4 financial performance exceeded expectations, with a narrowed loss of $0.01 per share, an 80% improvement year-over-year, and sales reaching $1.444 million, up 175.05% from the previous year, surpassing analyst projections. Additionally, RR announced a strategic partnership with Microsoft to develop agent AI capabilities for real-world robotic systems through an AI co-creation lab. This collaboration is expected to enhance the performance of RR's ADAM robots and expand intelligent automation in physical environments. The market's positive outlook on RR's prospects in AI and robotics drove the stock price up 44.6% in a single day, contributing to a year-to-date gain of 70.6%.

Acumen Pharmaceuticals, Inc.: Overnight gain 30.8%, Analyst upgrade and Alzheimer's drug potential drive bullish sentiment, boosting stock performance.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company founded in 1996, is at the forefront of developing innovative therapies targeting the underlying causes of Alzheimer's disease. This progressive neurodegenerative disorder, which primarily affects brain function, leads to a gradual decline in memory and cognitive abilities, and can ultimately be fatal. The company's research efforts are concentrated on pioneering disease-modifying approaches, aiming to address this critical unmet medical need. By focusing on the root causes of Alzheimer's, Acumen Pharmaceuticals seeks to revolutionize treatment options for patients suffering from this debilitating condition. As the global population ages and the prevalence of Alzheimer's disease continues to rise, Acumen's potential breakthrough therapies could have significant implications for both patients and the healthcare industry at large. Investors and industry observers are closely monitoring the company's progress in this high-stakes field of neurodegenerative disease research.

Acumen Pharmaceuticals, Inc. (ABOS) experienced a significant stock price surge due to multiple factors. Notably, BTIG analyst Thomas Shrader maintained a "Buy" rating and raised the price target from $4 to $7, signaling confidence in the company's outlook. As a clinical-stage biopharmaceutical firm focusing on Alzheimer's disease treatments, ABOS's potential in this substantial medical market has garnered investor recognition. The stock's impressive 30.8% single-day gain, contributing to a 28.9% year-to-date increase, has attracted additional investors, creating a positive feedback loop. This momentum reflects growing optimism surrounding Acumen's innovative approach to addressing the critical need for effective Alzheimer's therapies, potentially positioning the company for continued growth in the biotech sector.

The Top 10 Daily Gainers in the USA market are listed as follows:

Editor's note: This content was generated by Sahm's in-house AI-enabled SaaS tool and was reviewed by our editing team. Risk and Disclaimer: The content provided above is solely for informational purposes and does not represent the views or positions of Sahm Platform. While we strive for accuracy, we cannot guarantee the authenticity or completeness of the information contained in the provided content. We strongly recommend that investors consult with a qualified investment advisor when deemed necessary. Sahm Platform neither provides investment advice nor makes any representations or warranties concerning the accuracy, reliability, or completeness of the information in the content provided above. By using Sahm Platform, you acknowledge that you have read, understood, and agreed to the terms set forth in this disclaimer.